Skip to main content
OpenTrials
Completed

NCT Number: NCT02924584

Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan

Breast cancer is the most common cancer in Taiwanese women. Most of them were diagnosed in relatively early stages. Only 700 metastatic breast cancer were registered in Official Cancer Registration 2012, while more than11,305 were registered as early breast cancer. With broadly application of aromatase inhibitors, hormonal-receptor-positive breast cancer patients can survive longer and longer. However, there is no prevalence of metastatic breast cancer can be available yet. NHIA database coverage is more than 90% population in Taiwan, thus it can be an appropriate surrogate of prevalence. In this retrospective database analysis, we will explore the real world experience on aromatase inhibitor use for breast cancer in Taiwan.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ER/PR(+), Her2(-) Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

National Cheng Kung University

Tainan, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hormonal receptor positive, human epidermal growth factor receptor 2 negative breast cancer

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. clinical use of aromatase inhibitors in breast cancer

    Time frame: base line, up to 60 months

    duration of treatment

Secondary outcomes

  1. prevalence

    Time frame: base line up to 60 months

    The prevalence of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.

  2. dose exposure

    Time frame: base line, up to 60 months

    The dosage pattern of breast cancer with positive hormonal receptors with routine practice in Taiwan.

  3. overall survival

    Time frame: base line, up to 60 months

    The overall survival of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.

  4. treatment cost

    Time frame: base line, up to 60 months

    The treatment cost of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

THE TREATMENT FOR RECURRENT FEMALE BREAST CANCER AFTER INITIAL ENDOCRINE THERAPY AMONG TAIWANESE POPULATION

Important dates

Study start
2017
Primary completion
2017
Study completion
2018
First posted
Oct 5, 2016
Registry last updated
Jun 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.